Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenzhiling (SZL) is a Traditional Chinese Medicine (TCM) compound formulation approved in China for the treatment of mild to moderate Alzheimer's disease. It is an oral liquid composed of multiple herbal ingredients and has demonstrated efficacy in improving cognitive function and behavioral symptoms associated with Alzheimer's disease. Preclinical studies indicate that its mechanism involves promoting myelin repair and reducing β-amyloid plaque deposition, potentially through modulation of the PI3K/Akt-mTOR signaling pathway. Clinical research suggests it may delay progression of behavioral and psychological symptoms in Alzheimer's patients[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shenzhiling.